PT1556489E - Composi??o farmac?utica para a prepara??o de um medicamento destinado a tratar e/ou a prevenir uma patologia ligada a uma conduta obsessiva ou a obesidade - Google Patents

Composi??o farmac?utica para a prepara??o de um medicamento destinado a tratar e/ou a prevenir uma patologia ligada a uma conduta obsessiva ou a obesidade Download PDF

Info

Publication number
PT1556489E
PT1556489E PT03767876T PT03767876T PT1556489E PT 1556489 E PT1556489 E PT 1556489E PT 03767876 T PT03767876 T PT 03767876T PT 03767876 T PT03767876 T PT 03767876T PT 1556489 E PT1556489 E PT 1556489E
Authority
PT
Portugal
Prior art keywords
treating
pharmaceutical composition
obesity
medicine
preparing
Prior art date
Application number
PT03767876T
Other languages
English (en)
Inventor
Val Rie Compan
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Publication of PT1556489E publication Critical patent/PT1556489E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT03767876T 2002-10-31 2003-10-31 Composi??o farmac?utica para a prepara??o de um medicamento destinado a tratar e/ou a prevenir uma patologia ligada a uma conduta obsessiva ou a obesidade PT1556489E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0213725A FR2846559B1 (fr) 2002-10-31 2002-10-31 Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle

Publications (1)

Publication Number Publication Date
PT1556489E true PT1556489E (pt) 2011-05-31

Family

ID=32104388

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03767876T PT1556489E (pt) 2002-10-31 2003-10-31 Composi??o farmac?utica para a prepara??o de um medicamento destinado a tratar e/ou a prevenir uma patologia ligada a uma conduta obsessiva ou a obesidade

Country Status (12)

Country Link
US (3) US8859537B2 (pt)
EP (1) EP1556489B1 (pt)
JP (1) JP4852245B2 (pt)
AT (1) ATE497003T1 (pt)
AU (1) AU2003292310A1 (pt)
CA (1) CA2503546C (pt)
DE (1) DE60335892D1 (pt)
DK (1) DK1556489T3 (pt)
ES (1) ES2362092T3 (pt)
FR (1) FR2846559B1 (pt)
PT (1) PT1556489E (pt)
WO (1) WO2004042063A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2846559B1 (fr) * 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
US20060204599A1 (en) * 2005-03-14 2006-09-14 Wheat Jared R Dietary supplement and method of using same
CA2808630A1 (en) 2010-08-19 2012-02-23 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
FR3093419B1 (fr) * 2019-03-08 2021-06-18 Univ Grenoble Alpes Composition et procédé associé de mesure de l’observance thérapeutique
CA3136328A1 (en) * 2019-04-09 2020-10-15 The Trustees Of Columbia University In The City Of New York Prophylactic efficacy of serotonin 4 receptor agonists against stress
CN115581201A (zh) * 2022-08-26 2023-01-10 云南省农业科学院花卉研究所 以茎段为外植体诱导的二倍体月季f1-61的植株再生方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2127117C (en) * 1992-11-03 2001-02-13 Jonathan A. Bard Dna encoding a human serotonin receptor (5-ht4b) and uses thereof
US5472866A (en) * 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
CA2237582C (en) * 1996-02-15 2009-04-14 Janssen Pharmaceutica N.V. Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors
JP2002542287A (ja) * 1999-04-28 2002-12-10 レスピラトリウス アクチボラゲット 医 薬
GB9913850D0 (en) * 1999-06-14 1999-08-11 Janssen Pharmaceutica Nv Cloning and expression of a novel receptor
FR2811989A1 (fr) * 2000-07-18 2002-01-25 Sanofi Synthelabo Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique
FR2846559B1 (fr) * 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle

Also Published As

Publication number Publication date
FR2846559B1 (fr) 2007-06-15
US8859537B2 (en) 2014-10-14
US20130274293A1 (en) 2013-10-17
JP4852245B2 (ja) 2012-01-11
EP1556489A1 (fr) 2005-07-27
CA2503546A1 (fr) 2004-05-21
CA2503546C (fr) 2014-02-11
EP1556489B1 (fr) 2011-01-26
WO2004042063A1 (fr) 2004-05-21
JP2006520319A (ja) 2006-09-07
FR2846559A1 (fr) 2004-05-07
US20090124592A1 (en) 2009-05-14
US9168250B2 (en) 2015-10-27
US8436021B2 (en) 2013-05-07
ES2362092T3 (es) 2011-06-28
DE60335892D1 (de) 2011-03-10
US20060116341A1 (en) 2006-06-01
AU2003292310A1 (en) 2004-06-07
DK1556489T3 (da) 2011-05-16
ATE497003T1 (de) 2011-02-15
WO2004042063A8 (fr) 2005-08-11

Similar Documents

Publication Publication Date Title
MY151032A (en) Treatment of tnf? related disorders
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
BR0111898A (pt) Métodos de tratamento de doenças de proliferação celular, e de um distúrbio associado com a atividade de cinesina ksp, método de inibição da cinesina ksp, composto, método de triagem de moduladores da cinesina kps, e, método de triagem de compostos que se ligam à cinesina ksp
MXPA05006569A (es) Compuestos que inhiben la proteina cinasa-2 activada por la proteina cinasa activada por el mitogeno.
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
BR0306988A (pt) Piridazinonas substituìdas como inibidores de p38
NO20045429L (no) Kombinasjon av organiske forbindelser
NO20045354L (no) Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
DK1143955T3 (da) En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes
NO20051304L (no) Agonisme av 5HT2a reseptoren for behandling av termoregulatorisk dysfunksjon
DK1456380T3 (da) SMAD7-inhibitorer til behandling af CNS-sygdomme
PT1556489E (pt) Composi??o farmac?utica para a prepara??o de um medicamento destinado a tratar e/ou a prevenir uma patologia ligada a uma conduta obsessiva ou a obesidade
MXPA05001712A (es) Bifenilcarboxamidas sustituidas con n-aril piperidina como inhibidores de la secrecion de apolipoproteina b.
EA200702212A1 (ru) Способ лечения или профилактики разрушения кости или остеопороза
BR0315247A (pt) Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit
EA200501865A1 (ru) Аналоги тиовольфраматов и их применение
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
WO2006063256A3 (en) Treatment using d-threo methylphenidate
BRPI0408984A (pt) método para tratar uma condição de doença mediada por células neutrofìlicas em um paciente, e, uso de um composto de ligação de histamina
MY141048A (en) Morpholine derivatives as norepinephrine reuptake inhibitors
ZA202311101B (en) Tm4sf19 inhibitor and uses thereof
WO2003014114A3 (en) Substituted amine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors